Apexigen, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in San Carlos, California and currently employs 20 full-time employees. The company went IPO on 2021-02-02. The firm is focused on discovering and developing antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents designed to harness the patient’s immune system to combat and eradicate cancer. The company has developed a clinical-stage candidate, namely sotigalimab (sotiga or APX005M), which is a humanized agonist antibody. The company also has various preclinical and research-stage antibodies it discovered using its APXiMAB platform. The company is focused on completing ongoing clinical and manufacturing activities for the sotiga program. The Company’s licensees are advancing five product candidates in clinical development that were enabled by discoveries from its APXiMAB platform. APX005M is under Phase II clinical development for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction cancers and melanoma, in combination with chemotherapy, radiation therapy and immunotherapy.

Industry: Pharmaceutical Preparations Peers: Mink Therapeutics Inc Carisma Therapeutics Inc MARIZYME, INC. iBio Inc LUMOS PHARMA, INC. Dianthus Therapeutics Inc Onkure Therapeutics Inc Spero Therapeutics Inc Taysha Gene Therapies Inc